Prophylactic Cranial Irradiation Improved Survival in Metastatic SCLC
This video examines the results of a retrospective study that compared chemotherapy alone or with prophylactic cranial irradiation in extensive-stage SCLC patients with no brain metastases.
The role of prophylactic cranial irradiation (PCI) in patients with extensive-stage small-cell lung cancer (SCLC) remains controversial, with previous studies reporting conflicting results.
In this video, Sonam Sharma, MD, of the University of Pennsylvania, Philadelphia, discusses results of a National Cancer Database study that looked at metastatic SCLC patients without brain metastases who received either chemotherapy (n = 3,784) or chemotherapy plus PCI (n = 473).
Sharma presented the results of the study (abstract 11) at the 2017 Multidisciplinary Thoracic Cancers Symposium, held March 16–18 in San Francisco.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F7d7dfad7849391f4be3ebd2cf39c24f5369cfcd1-1200x1176.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).")
